Early Real-World Outcomes Among Patients (Pts) with IgAN Receiving Iptacopan: Analysis of the APPRISE-IgAN Data Platform (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO0460; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Funding Commercial Support – Novartis Pharmaceuticals Corporation Background A Pt Platform for Real-world data on Iptacopan and Atrasentan in the United StatEs for pts with IgAN (APPRISE-IgAN) captures real-world data on US pts with IgAN prescribed iptacopan (complement factor B inhibitor) and/or atrasentan (endothelin type A receptor antagonist). Conclusion In this real-world analysis, meaningful proteinuria and hematuria reduction in a population with IgAN was observed with iptacopan use, suggesting early clinical benefit. Ongoing data collection will provide more valuable information."
Clinical • Real-world • Real-world evidence • Glomerulonephritis • IgA Nephropathy • Renal Disease • CFB
|
|
Briana C. Ndife; Helen Trenz; Hamid Moradi; Anirban Bose; Claire Buchan; Tayler Buchan; Eugene Baraka; Pietro A. Canetta; Mohanram Narayanan
|